Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate

The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release topiramate (phentermine/topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweeting, Arianne N, Tabet, Eddy, Caterson, Ian D, Markovic, Tania P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926768/
https://www.ncbi.nlm.nih.gov/pubmed/24550678
http://dx.doi.org/10.2147/DMSO.S38979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926768/
https://www.ncbi.nlm.nih.gov/pubmed/24550678
http://dx.doi.org/10.2147/DMSO.S38979

Ejemplares similares